Site is Being Upgraded

Natural product-based Lifespan extension therapy: A pharmaceutical mixture (LA) encompassing Luteolin and Apigenin, isolated from Salvia and chamomile,  respectively, may increase life span via up-regulation of its target gene BubR1, 31/December/2017, 1.13 am

 Natural product-based antiviral therapy: Resveratrol, a longevity-promoting compound, inhibits Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1,  respiratory syncytical ,  Sindbis, and SFV viruses by increasing the Levels of the Antiviral Proteins IFITM3, & Interferon-stimulated gene 15, 31/December/2017,  12.36 am
December 30, 2017
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  α-linoleic acid, Epicatechin and Matrine (LAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 1/January/2018, 5.23 am
December 31, 2017
Show all

 What they say: Introduction: 

A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the journal  “EMBO”, by Prof Sinclair, North BJ, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based Lifespan extension therapy: A pharmaceutical mixture (LA) encompassing Luteolin and Apigenin, isolated from Salvia and chamomile,  respectively, may increase life span via up-regulation of its target gene BubR1


What is known? 

Both Luteolin and Apigenin have been shown to possess anti-hyperglycemic property. However, the exact mechanism of action of these natural product-derived compounds is far from clear.


From Research Findings to Therapeutic Opportunity: 

This study suggests, for the first time, that a pharmaceutical mixture encompassing Luteolin and Apigeninby increasing the expression of its target gene, it may: (a) increase the expression of BuBR1; (b) decrease the expression of p70 S6 Kinase; and (c) regulate the expression of a number of longevity-promoting molecules (Fig. 1).

[easy_payment currency=”USD”]

Figure 1. A therapeutic mix encompassing Luteolin and Apigenin may extend  mammalian life span via up regulation of BuBR1 and down regulation of p70 S6 Kinase

Figure 2. The chemical structure of Luteolin and Apigenin.

Thereby, it may: (1) increase insulin sensitivity; (2) increase thermogenesis, lipolysis and oxidative metabolism; (3) inhibit obesity; (4) attenuate cognitive impairment; (5) delay diseases of aging; (6) slow down cardiac aging; (7) promote resistance to bone, immune and motor dysfunction; (8) promote tissue rejuvenation; and (9) prolong median life span. Thus, pharmacological formulations encompassing “Luteolin and Apigenin or their analogues, either alone or in combination with other drugs may be used to extend the lifespan of an individual (fig. 1).


Details on the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $500#

Undisclosed mechanistic information: How a pharmaceutical mix encompassing Luteolin and Apigenin increases the expression of BubR1 and extends mammalian life-span

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

# Research cooperation


References

Web: http://genomediscovery.org or http://newbioideas.com

CitationBoominathan, L., Natural product-based Lifespan extension therapy: A pharmaceutical mixture (LA) encompassing Luteolin and Apigenin, isolated from Salvia and chamomile,  respectively, may increase life span via up-regulation of its target gene BubR1, 31/December/2017, 1.13 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.